Perceived Effectiveness of Vaping Prevention Ads Among Adolescents and Young Adults
Public ClinicalTrials.gov record NCT07116837. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of the Aim 2 study is to assess the perceived effectiveness of vaping prevention ads among adolescents and young adults and identify which features of video ads predict perceived message effectiveness. Participants will include adolescents aged 13-17 and young adults aged 18-20 who live in the US and who are susceptible to vaping or who currently vape. In an online survey, participants will be randomized to view five randomly selected vaping prevention ads identified from a previous content analysis. After viewing the videos, participants will rate each video on the perceived message effectiveness scale and respond to questions about vaping appeal and urge to vape. The survey will take 15-20 minutes. A follow-up survey of a subset of participants will be conducted around two weeks after they have been exposed to vaping prevention video ads in the baseline survey. Participants will view a total of six videos, including the five videos they watched previously, shown one at a time, along with one "decoy" video ad. After watching each video ad, participants will indicate whether they remember seeing the ad in the survey they took around two weeks prior. The survey will take 10-15 minutes.
Study identification
- NCT ID
- NCT07116837
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Not applicable
- Enrollment
- 3,113 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 13 Years to 20 Years
- Sex
- All
- Healthy volunteers
- Accepts healthy volunteers
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Sep 30, 2025
- Primary completion
- Jun 13, 2026
- Completion
- Jun 13, 2026
- Last update posted
- Jun 30, 2026
2025 – 2026
United States locations
- U.S. sites
- 1
- U.S. states
- 1
- U.S. cities
- 1
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of North Carolina, Chapel Hill | Chapel Hill | North Carolina | 27599 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT07116837, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 30, 2026 · Synced Sep 13, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT07116837 live on ClinicalTrials.gov.